White House

A White House ceremony on Tuesday marked the end of the "X-waiver" requirement.

Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy, applauded the elimination of the certification on Twitter: 

The NACDS-backed move comes out of the inclusion of the bipartisan Mainstreaming Addiction Treatment (MAT) Act in the Fiscal Year (FY) 2023 Omnibus Appropriations Act, which included the abolishment of the X-waiver.

Importantly, the law change removes the federal requirement for practitioners to have a DATA-Waiver registration (a.k.a. an “X-waiver”) to prescribe buprenorphine for the treatment of opioid use disorder.

Notably, the removal of the X-waiver eliminates the statutory caps on the number of patients that a qualifying practitioner can treat — as long as the prescriber otherwise has a standard DEA registration. This change increases patients’ access to medication-assisted treatment (MAT). It also simplifies for pharmacies the administrative processes around filling what are now X-waiver prescriptions.

Pharmacists and pharmacy teams have a critical role to play in curbing prescription opioid misuse and abuse — and NACDS continues to advocate for policies that would enhance Americans’ access to mental health and substance abuse treatment. Removing the X-waiver will help pave the way for enhanced access to MAT services for patients who struggle with opioid addiction.

The December measure also included the bipartisan, NACDS-backed INFORM Consumers Act, which requires online platforms that allow for third-party sellers of consumer products to verify the identity of high-volume third-party sellers to help prevent organized retail crime.

Share this story:

Related Posts

    NACDS Submits Comments to FDA on Expanding Access to Nonprescription Drugs

    Comments emphasize the importance of coordinated policy and operational alignment to support affordable and seamless patient access.

    NACDS Praises FDA Move to Delay Enforcement of Certain DSCSA “Track and Trace” Requirements Until November 27, 2024

    This delay is an acknowledgement of a much needed delay – advocated by NACDS, along with supply chain and other pharmacy partners – to address technical and operational issues that had the potential to create supply chain disruptions and adversely impact patients’ access to needed medications.

    Poll Shows Support for Extending Implementation Date for Prescription Drug “Track and Trace” to Prevent Drug-Shortage Risk

    Seventy-two percent who support track and trace, and 70% of those who have experienced a medicine or health product shortage, back an extension of the DSCSA’s final implementation date.